[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Staci Gruber, Ph.D.\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":75},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,2,0,[8,51],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":26,"conditions":27,"keywords":31,"overallStatus":38,"whyStopped":4,"lastUpdateSubmitDate":39,"lastUpdatePostDateStruct":40,"startDateStruct":43,"completionDateStruct":45,"leadSponsor":47,"locationsCount":50},"100648926","phase-1-assessing-the-mechanisms-and-impact-of-a-novel-cannabinoid-product-for-gynecologic-pain-100648926",false,"NCT07728695","Assessing the Mechanisms and Impact of a Novel Cannabinoid Product for Gynecologic Pain","PAIN-GP: Project Assessing the Mechanisms and Impact of a Novel Cannabinoid Product for Gynecologic Pain","PAIN-GP","Inclusion Criteria:\n\n* Provides informed consent\n* Sex assigned female at birth\n* Capable of having menstrual cycles\n* Aged 21+\n* Endorses one of the following gynecologic pain conditions: endometriosis, adenomyosis, chronic pelvic inflammatory disease (PID)\n* Stable medication\u002Fpsychotherapy regimens for at least 3 months prior to starting the study, including hormonal contraceptives\n\nAdditional inclusion criteria for those in the PK subgroup:\n\n* Willingness to participate in the PK procedures (i.e., agree to an indwelling catheter with repeated blood collection)\n\nExclusion Criteria:\n\n* Meets criteria for DSM-5 classification of current substance use disorder, psychotic disorder, bipolar disorder, or an eating disorder\n* Currently uses cannabinoid products\n* Positive urine pregnancy test, are trying to become pregnant, or are currently breastfeeding\n* Presence of a serious or unstable medical illness, including liver\u002Fkidney disease, cardiovascular disease, neurological disorder, and conditions or medications that impact drug absorption or gastric emptying (e.g., GLP-1 agonists)\n* Comorbid neuropathic pain or cancer-related pain\n* Disclosure of a genetic polymorphism affecting CYP2C9 function\n* Liver function test (LFT) values \\>3x the upper limit of normal (ULN) at the baseline visit","FEMALE","21 Years",{"count":20,"type":21},60,"ESTIMATED","INTERVENTIONAL",[24,25],"PHASE1","PHASE2","Despite recent increases in both medical and recreational cannabis use in the United States and globally, little research has been conducted to determine the potential applications for womens health. A variety of medical cannabis and hemp-derived products on the marketplace claim to hold efficacy for many womens health-related conditions, including gynecologic pain. This 7-day study of individuals living with endometriosis, adenomyosis, or chronic pelvic inflammatory disease (PID), will identify specific targets and mechanisms underlying the potential impact of a hemp-derived, full-spectrum, high-CBD product in individuals with gynecologic pain.",[28,29,30],"Endometriosis","Adenomyosis","Chronic Pelvic Inflammatory Disease",[32,33,34,35,36,37],"cannabidiol","gynecologic pain","cannabinoid","endometriosis","adenomyosis","pelvic inflammatory disease","RECRUITING","2026-07-22",{"date":41,"type":42},"2026-07-27","ACTUAL",{"date":44,"type":21},"2026-09",{"date":46,"type":21},"2029-01",{"name":48,"class":49},"Staci Gruber, Ph.D.","OTHER",1,{"id":52,"slug":53,"hasResults":11,"nctId":54,"briefTitle":55,"officialTitle":55,"acronym":4,"eligibilityCriteria":56,"healthyVolunteers":11,"sex":57,"minAge":18,"maxAge":4,"enrollmentInfo":58,"targetDuration":4,"studyType":22,"phases":60,"briefSummary":61,"conditions":62,"keywords":64,"overallStatus":38,"whyStopped":4,"lastUpdateSubmitDate":68,"lastUpdatePostDateStruct":69,"startDateStruct":71,"completionDateStruct":73,"leadSponsor":74,"locationsCount":50},"100361316","phase-2-pain-a-project-assessing-the-impact-of-a-novel-cannabinoid-product-100361316","NCT03984565","PAIN: A Project Assessing the Impact of a Novel Cannabinoid Product","Inclusion Criteria:\n\n* Subject has provided informed consent\n* Subject is 21 or older\n* Subject is fluent in English\n* Subject endorses a musculoskeletal chronic pain condition including, but not limited to, chronic pain due to injury, arthritis (including osteoarthritis and rheumatoid arthritis), bursitis, etc.\n\nExclusion Criteria:\n\n* Non-fluent English speakers\n* Estimated IQ \\\u003C 75\n* A history of head injury or loss of consciousness greater than 5 minutes\n* Currently uses CBD products regularly\n* Female subjects will be excluded if they have a positive urine pregnancy test, are trying to become pregnant, or are currently breastfeeding\n* Presence of a serious or unstable medical illness, including liver, kidney, or cardiovascular disease (hyper\u002Fhypotension, cardiac disorders), or neurological disorder (including seizure disorder)\n* Primary neuropathic pain or cancer-related pain; patients experiencing neuropathic pain secondary to musculoskeletal pain will be allowed to enter the study\n* Disclosure of a genetic polymorphism affecting CYP2C9 function","ALL",{"count":59,"type":21},25,[25],"This study is a clinical trial of a high-cannabidiol (CBD) sublingual product compared to placebo for 9 weeks in patients with chronic pain conditions. The study will assess the impact of CBD on chronic pain symptoms, conventional medication use, clinical state, quality of life, cognition, and biomarkers.",[63],"Chronic Pain",[65,66,67],"Cannabidiol","Medical Cannabis","Industrial Hemp","2026-03-24",{"date":70,"type":42},"2026-03-30",{"date":72,"type":42},"2024-06-27",{"date":44,"type":21},{"name":48,"class":49},""]